ATE549013T1 - Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren - Google Patents

Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Info

Publication number
ATE549013T1
ATE549013T1 AT10160099T AT10160099T ATE549013T1 AT E549013 T1 ATE549013 T1 AT E549013T1 AT 10160099 T AT10160099 T AT 10160099T AT 10160099 T AT10160099 T AT 10160099T AT E549013 T1 ATE549013 T1 AT E549013T1
Authority
AT
Austria
Prior art keywords
administration
reduced volume
glatiramer acetate
volume formulation
formulation
Prior art date
Application number
AT10160099T
Other languages
German (de)
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE549013T1 publication Critical patent/ATE549013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT10160099T 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren ATE549013T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
ATE549013T1 true ATE549013T1 (de) 2012-03-15

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10160099T ATE549013T1 (de) 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Country Status (19)

Country Link
US (3) US20110060279A1 (enExample)
EP (2) EP2275086B1 (enExample)
JP (1) JP2012533540A (enExample)
AR (1) AR077484A1 (enExample)
AT (1) ATE549013T1 (enExample)
AU (1) AU2010273234A1 (enExample)
BR (1) BR112012000878A2 (enExample)
CA (1) CA2697570C (enExample)
DK (1) DK2275086T3 (enExample)
EA (1) EA201270167A1 (enExample)
ES (1) ES2383347T3 (enExample)
HR (1) HRP20120349T1 (enExample)
IL (1) IL217240A0 (enExample)
MX (1) MX2012000687A (enExample)
PL (1) PL2275086T3 (enExample)
PT (1) PT2275086E (enExample)
RS (1) RS52367B (enExample)
WO (1) WO2011008274A2 (enExample)
ZA (1) ZA201200586B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
HUE031282T2 (hu) 2009-08-20 2017-06-28 Yeda Res & Dev Alacsony gyakoriságú glatiramer acetát terápia
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
KR101694645B1 (ko) * 2012-08-20 2017-01-09 케어베이 유럽 리미티드 자동 주입 장치
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
AU2014229581B2 (en) * 2013-03-08 2016-12-22 Teva Pharmaceutical Industries Limited Re-useable injector device for syringe
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
PE20151577A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP6550393B2 (ja) 2014-02-26 2019-07-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼内インプラント送出装置及び使用方法
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
DK3506921T3 (da) 2016-08-31 2023-07-31 Mapi Pharma Ltd Depotsystemer, der omfatter glatirameracetat
CA3042493A1 (en) * 2016-11-02 2018-05-11 To Pharmaceuticals Llc Combination therapy of cbd and copaxone
CN110087530A (zh) 2016-12-07 2019-08-02 普罗根尼蒂公司 胃肠道检测方法、装置和系统
US11167003B2 (en) 2017-03-26 2021-11-09 Mapi Pharma Ltd. Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Ｈｉｖリザーバーを排除し、ウイルス負荷を低減する処置
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3673317D1 (de) * 1985-10-11 1990-09-13 Duphar Int Res Automatische spritze.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) * 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
WO2004047893A1 (de) * 2002-11-25 2004-06-10 Tecpharma Licensing Ag Autoinjektor mit rückstellbarer auslösesicherung
WO2005032482A2 (en) * 2003-10-03 2005-04-14 Bayhill Therapeutics, Inc. Treatment of demyelinating autoimmune disease with modified ordered peptides
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
WO2006050122A1 (en) * 2004-10-29 2006-05-11 Sandoz Ag Processes for preparing glatiramer
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
TWI542374B (zh) * 2006-06-30 2016-07-21 艾伯維生物技術有限責任公司 自動注射裝置
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
US20090149541A1 (en) 2007-11-28 2009-06-11 Yafit Stark Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
CA2697570C (en) * 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration

Also Published As

Publication number Publication date
AU2010273234A1 (en) 2012-02-23
US20110066112A1 (en) 2011-03-17
RS52367B (sr) 2012-12-31
CA2697570A1 (en) 2010-06-22
CA2697570C (en) 2011-11-01
HK1152249A1 (en) 2012-02-24
EP2275086A1 (en) 2011-01-19
WO2011008274A3 (en) 2011-09-22
IL217240A0 (en) 2012-02-29
ES2383347T3 (es) 2012-06-20
DK2275086T3 (da) 2012-07-09
PL2275086T3 (pl) 2012-09-28
ZA201200586B (en) 2013-10-30
HRP20120349T1 (hr) 2012-07-31
US9018170B2 (en) 2015-04-28
JP2012533540A (ja) 2012-12-27
US20110060279A1 (en) 2011-03-10
EP2275086B1 (en) 2012-03-14
WO2011008274A4 (en) 2011-11-10
BR112012000878A2 (pt) 2019-09-24
AR077484A1 (es) 2011-08-31
WO2011008274A2 (en) 2011-01-20
MX2012000687A (es) 2012-09-07
EA201270167A1 (ru) 2012-08-30
US7855176B1 (en) 2010-12-21
PT2275086E (pt) 2012-05-18
EP2453907A2 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
ATE549013T1 (de) Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
HUS1900031I1 (hu) Hatóanyagok légúti beadása
ES2618221T8 (es) Dispositivo de administración de prótesis vascular y método de uso
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
IL230786A0 (en) Heterocyclic derivative and pharmaceutical drug
EP2888265A4 (en) BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC PROCEDURES THEREWITH
EP2563435A4 (en) ADMINISTRATION OF ULTRA PURE NITROGEN MONOXIDE (NO)
HRP20170929T1 (hr) Farmaceutski pripravci i odgovarajući postupci za isporuku
PT2780022T (pt) Preparações farmacêuticas de células epr humanas e suas utilizações
LT2603232T (lt) Stabilios linaklotido vaisto formos
IL215497B (en) Oxadiazole derivatives and pharmaceutical compositions containing them
HUE054922T2 (hu) Riszperidon és/vagy Paliperidon implantátum készítmény
DK2529756T3 (da) Risperidon- og/eller paliperidon-implantatformulering
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
BR112012003286A2 (pt) formulações farmacêuticas contra o mau uso dos medicamentos
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
EP2547328A4 (en) CCR7 LIGANDEN ADMINISTRATION AND CO-ADMINISTRATION IN AN IMMUNOTHERAPY
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2408912A4 (en) FOXM1 PEPTIDES AND VACCINES CONTAINING THEM
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
FI20135152L (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
PL2568980T3 (pl) Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania
SI2525789T1 (sl) Farmacevtske formulacije naproksena za enkapsulacijo v mehko želatino in njihove kombinacije
EP2532665A4 (en) BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF